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Abstract- Psoriasis is a chronic and inflammatory dermatologic disease. Psoriasis may predispose to 
cardiovascular disease and diabetes. However, the role of tumor necrosis factor (TNF) inhibitor in mediating 
this risk is controversial. Regarding frequent use of infliximab in psoriasis, and the hypothesis that anti TNF-
α treatment may increase Body Mass Index (BMI) and alter lipid profile in these patients, the aim of this 
study was to assess changes in BMI and Lipid Profile and level of leptin in Psoriatic Patients under Treatment 
of Standard Protocol of Infliximab in a 24 week period. This study was accomplished as a before-after study. 
Twenty-seven psoriatic patients were included, and standard infliximab therapy was applied. All patients 
underwent 3 times of blood collection and in each session; LDL, HDL, Total Cholesterol, Triglycerides, 
Leptin, and PASI score were measured at the start of the study and at the 12th and 24th week of follow-up. 
Twenty-five patients consisted of 18 (72%) male and 7 (28%) female subjects were evaluated. The mean age 
of the patients was 36.91±13.31 years. PASI score demonstrated significant decrease after 24 weeks; 
however, BMI and HDL and leptin showed a significant increase during treatment. Significant negative 
correlation was seen between Leptin and PASI score changes (r=0.331, P=0.042). HDL and BMI had the 
most correlations with leptin (positive correlation) and PASI score (negative correlation). Results 
demonstrated a dramatic decrease in PASI, increase in BMI and HDL and increased in leptin; somewhat 
correlated to each other. These results suggest that patients taking infliximab should take more care of their 
weight and lipid profile, while on treatment.  
© 2016 Tehran University of Medical Sciences. All rights reserved.  
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Introduction 
 
Psoriasis is a chronic and recurrent dermatologic 
disease, which despite several treatment protocols, has 
no definite cure (1). The etiology of this disease consists 
of epidermal growth and differentiation disturbance, and 
biochemical, immunological and vascular disorders. It 
affects both sexes equally, and its prevalence ranges 
0.1% to 11.8% in different populations (2-4). Several 
types of psoriasis have been demonstrated, and 
therefore, different types of treatment have been 
proposed (5). 
Anti-Tumor necrotizing factor type alpha (TNF-α) 
drugs are widely used in immunologic and rheumatic 
diseases such as rheumatoid arthritis and psoriasis. TNF-
α is a type of cytokine produced by the immune system 
in rheumatic diseases. This biochemical marker reduces 
when the immunologic response and inflammation 
decreases resulting by treatment of anti-TNF-α drugs 
such as infliximab (6-8). This biomarker can decrease 
appetite and body weight and Body Mass Index (BMI). 
TNF-α induces synthesis of catabolic hormones such as 
Insulin-like Growth Hormone-1 and increases lipolysis 
in adipose tissue, resulting in lower leptin production (9-
10). Counter-wise, it is hypothesized that anti TNF-α 
treatment may increase BMI. This weight gain can be 
problematic in some cases, which can influence 
compliance with the treatment. Furthermore, increased 
inflammation in psoriatic patients potentially increases 
cardiovascular (CVD) risk factors and along with 
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increased BMI and systematic inflammation, the odds of 
CVD exponentially increase. 
Therefore, regarding frequent use of infliximab in 
psoriasis, the aim of this study was to assess the change 
in Body Mass Index and Lipid Profile and level of leptin 
in Psoriatic Patients under Treatment of Standard 
Protocol of Infliximab 
  
Materials and Methods 
 
Design 
Patients with the confirmed diagnosis of Psoriasis 
were selected from January 2013 till January 2014. 
Patients were selected from those referred to the 
dermatologic referral center of Tehran University of 
Medical Sciences affiliated hospital; Razi. We used 
convenient sampling and patients were entered 
regarding eligibility criteria. The clinical assessment of 
the disease was based on Psoriasis Area and Severity 
Index (PASI) score that made it possible to select 
patients who needed advanced treatment. Infliximab was 
prescribed to patients suffering from moderate to severe 
forms of the disease according to clinical scores. Based 
on previous studies patients with PASI score more than 
10 were classified as the moderate to severe form of 
psoriasis (3,24). Prior to the study, the patients were 
asked if they previously experienced any 
hypersensitivity reactions after using any drugs 
especially anti-TNF agents.  
Infliximab 5 mg/kg was prescribed intravenously at 
the initial time and then at the second and the sixth week 
and then every 8 weeks up to 48 weeks. The patients 
were advised to refer for clinical assessment after 12 and 
24 weeks of the first session. Before the initiation of the 
study and after anti-TNF therapy BMI, blood pressure, 
serum triglyceride and cholesterol, LDL and HDL and 
PASI score were all assessed in our patients. Thyroid 
stimulating hormone (TSH) and creatinine were also 
checked before and after the therapeutic period. BMI 
was achieved by weight (kg) to the square of height 
(m2). Furthermore, all patients underwent Leptin 
measurement in all 3 sessions. 
 
Eligibility criteria 
According to our inclusion criteria, all included 
patients were checked if they intended to get pregnant or 
used any cytotoxic drugs simultaneously. Also, 
lactation, poor cooperation and difficult accessibility for 
follow-up, the presence of positive beta-HCG or 
intolerable side effects during the study were considered 
as other exclusion criteria. During the study, patients 
were checked for probable complications such as 
activation of latent infections (exp.; Tuberculosis and 
new positive PPD), hematologic changes, and 
deterioration of the initial dermatologic findings and any 
new onset of the disease. Therapeutic approach was 
changed or modified regarding the patient’s problem. 
Patients’ diet and physical activities were asked in every 
session, and if there were any significant changes during 
the study, the patients were excluded. 
 
Assays 
10 ml of venous blood was taken from subjects in the 
morning after overnight fast. Glucose (mg/dl), TG 
(mg/dl), HDL-C (mg/dl), levels were measured using 
photometric assay with intra- and inter-assay CV less 
than 2% (Pars Azmoon Company; Iran) with Hitachi 
(Japan) photo-analyzer. Leptin (ng/ml) levels were 
measured using a radioimmunoassay kit from Linco 
Research (St Louis, USA) with intra- and inter-assay CV 
less than 5%. 
 
Ethical approval 
This study was approved by the research committee 
of Tehran University of Medical Sciences, and ethical 
approval was achieved by the related review board. 
Every person was oriented with the aim of the study via 
a written letter and signed the attached written consent. 
All personal information were preserved regarding 
Helsinki’s’ declaration. 
 
Statistical analysis 
All clinical and laboratory data and basic 
characteristics were entered into SPSS software version 
18 (PASW 18). Frequencies and percentages were used 
to show qualitative analysis and mean±SD was used to 
show quantitative analysis. Prior to any deductive 
analysis, we used one sample Kolmogorov-Smirnov test 
to check distribution pattern. Repeated measure 
ANOVA was used to check the progression of the 
disease or repeated laboratory findings within the time. 
Furthermore, Pearson correlation was used to find 
possible relations between variables. The significance 
level was considered less than 0.05. 
 
Results 
 
At the initial stage, 27 patients were included in the 
study; however, 2 patients were excluded due to 
Atherogenic diet and neotigazone (Acitretin) usage in 
the middle of the study. At the end, 25 patients were 
evaluated, consisted of 18(72%) male and 7(28%) 
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female subjects. The mean age of the patients was 
36.91±13.31 years, with no significant difference 
between genders. 
All patients underwent 3 measurements for PASI, 
BMI, and Leptin and lipid profile. As seen in table 1, 
PASI, BMI, and HDL had significant changes during the 
course of treatment after measurements in week 12 and 
24; PASI score was significantly reduced and a 
significant increase in BMI and HDL level was shown. 
However, no significant difference of these 
measurements was noticed among gender. 
 
Table 1. The mean of three times of Lipid Profile, BMI and leptin 
measurements and changes with treatment course and gender. HDL, Leptin, 
and BMI had significant changes in the treatment course. A significant 
difference was seen between males and females in HDL and Leptin. (*: Mann-
Whitney-U test, Ɨ: repeated measurement test)
 Total Male Female P* 
TG 
First 173.0±99.3 172.2±100.1 175.91±91.3 0.532 
Second 186.1±109.3 185.1±111.2 190.0±99.5 0.726 
Third 218.7±174.3 221.7±150.2 212.1±199.9 0.921 
p Ɨ 0.141 0.116 0.203 
LDL 
First 101.9±38.1 101.3±37.9 103.0±34.1 0.867 
Second 97.2±40.1 97.0±40.0 97.6±39.3 0.902 
Third 90.5±41.8 90.2±41.5 91.1±41.1 0.822 
p Ɨ 0.074 0.061 0.08 
Cholesterol 
First 175.6±42.4 175.1±43.1 177.1±39.4 0.863 
Second 174.36±36.0 173.2±34.4 174.9±35.1 0.827 
Third 179.9±50.8 179.4±50.0 180.1±50.1 0.892 
p Ɨ 0.496 0.502 0.463 
HDL 
First 39.0±8.2 37.5±7.2 42.1±9.3 <0.001 
Second 40.92±10.8 38.6±7.6 42.9±10.2 <0.001 
Third 45.6±14.7 44.1±8.0 48.9±13.7 <0.001 
p Ɨ 0.004 0.003 0.005 
Leptin 
First 20.2±22.2 17.5±6.4 27.1±6.4 <0.001 
Second 31.31±22.9 29.2±19.0 29.2±19.76 <0.001 
Third 37.7±26.0 39.5±33.6 39.5±33.6 <0.001 
p Ɨ <0.001 <0.001 <0.001 
BMI 
First 26.2±5.1 26.3.±4.7 26.1.±4.9 0.529 
Second 27.2±4.5 27.3±3.9 27.1±4.0 0.556 
Third 28.8±5.1 29.0±4.6 28.5±5.0 0.591 
p Ɨ 0.014 0.011 0.021 
*: Mann-Whitney-U test, Ɨ: repeated measurement test 
 
 
As demonstrated in table 2, the correlation of Leptin 
and PASI with changes in BMI and lipid profile changes 
were assessed; a significant correlation was seen 
between Leptin and PASI score changes with changes in 
HDL and BMI. Furthermore, table 3 demonstrates 
details of each measurement corresponding to sampling 
times; HDL and BMI had the most correlations with 
leptin and PASI score. 
 
Table 2. Correlation assessment between changes (∆) of Leptin and PASI Score 
with lipid profile and BMI changes (second column) through the study period, 
changes in HDL and BMI were statistically correlated with changes in leptin and 
PASI.
 Correlation with 
Δ leptin Δ PASI 
ΔTG 45.72±150.5 r=0.1118, P=0.942 r=0.056, P=0.790 
ΔChol 4.3±35.38 r=0.218, P=0.331 r=0.255, P=0.219 
ΔHDL 6.6±10.23 r=0.389, P=0.041 r=0.310, P=0.023 
ΔLDL -11.4±28.9 r=-0.019, P=0.407 r=-0.219, P=0.293 
ΔBMI 0.58±1.29 r=0.489, P<0.001 r=0.558, P<0.001 
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Table 3. Correlation test between PASI score and Leptin levels 
with lipid profile and BMI; a significant correlation was 
detected among HDL and BMI measurements with PASI score 
and leptin level.
 
 Correlation 
# of 
sampling Leptin PASI 
TG 
1 r=0.07, P=0.736 r=0.169, P=0.408 
2 r=0.359, P=0.079 r=0.173, P=0.379 
3 r=0.297, P=0.141 r=0.463, P=0.017 
Total 
cholesterol 
1 r=0.178, P=0.384 r=0.155, P=0.449 
2 r=0.178, P=0.384 r=0.349, P=0.800 
3 r=0.251, P=0.216 r=0.280, P=0.165 
HDL 
1 r=0.305, P<0.001 r=-0.587, P<0.001 
2 r=0.384, P<0.001 r=-0.496, P<0.001 
3 r=0.321, P<0.001 r=-0.504, P<0.001 
BMI 
1 r=0.355, P=0.087 r=-0.072, P=0.369 
2 r=0.368, P=0.105 r=-0.296, P=0.021 
3 r=0.488, P=0.032 r=-0.547, P<0.001 
 
 
Discussion 
 
Our results demonstrated that patients treated with 
infliximab exhibit reduced PASI score, increased 
weight, leptin, and HDL; which all these three 
parameters more or less, had a correlation with each 
other; however, no significant change was observed in 
LDL and TG. The cause of leptin increase is maybe due 
to enhance biphasic excretion of leptin from adipocytes 
in minimum or maximum levels of TNFs (12). 
Nearly all studies regarding anti-TNF agents in 
rheumatic disease demonstrated significant changes in 
leptin serum levels; however, there are researchers who 
have stated otherwise. Magera et al., (13) and Nishio et 
al., (14) both demonstrated increase in leptin in 
infliximab treated RA patients. Unlike our study, Gay et 
al., (15) did not find any changes and Tokarczyk-Knapik 
et al., (16) found inverse changes. 
 
TNF and lipid profile 
There are several debates regarding TNF and lipid 
profile in rheumatic disease: Poloono et al., (17) 
demonstrated HDL rise by Adalimumab after 2 weeks 
and Castro et al., (18) demonstrated HDL rise after 2 
weeks of infliximab. However, there are some 
controversies regarding other lipids; e.g. in Castro et al., 
(18) study, VLDL and TG increases in arthritic psoriasis 
patients by infliximab. Cauza et al., (19) also 
demonstrated the same results. 
TNF is an inflammatory biomarker indicating 
infective, immunologic or rheumatologic reactions. TNF 
can induce TG and HDL increase, theoretically, by 
means of three pathways: 1-activating Insulin, TNF and 
Gi receptors and inducing free fatty acids (FFAs) release 
in the blood 2-activation of hepatocytes, which facilitate 
the change of FFA to TG by increasing intercellular 
citrates; 2-blocking activated lipoprotein lipase (LPL) in 
all cells. However, fast increase of TGs can activate 
negative feedbacks and stabilize this process (14-18). By 
reviewing this information, it seems that administering 
anti-TNF agents will deactivate these pathways and TG 
decreases in the result but most studies demonstrated 
that these changes are not significant or showed slight 
increase (like our study) and concluded that this slight 
changes (sometimes less than 10 mg/dl) are not that 
much important clinically (14-18). The debate regarding 
cholesterols does not fall far from TG. Animal models 
demonstrated a rise in LDL and TG by TNF injection in 
mice; however, nearly all published literature indicate 
that TNF induces a reduction in cholesterols (especially 
HDL) by interfering with LDL receptors, Apo-
lipoprotein A and B, and 7A1 and 7B1 cytochromes 
with no changes in HMG-co reductase action (12,17-
21). Therefore it is logical to conclude that Anti-TNF 
drugs will result in increased HDL. Furthermore, drugs 
such as infliximab can inhibit lecithin cholesterol 
acyltransferase and cholesteryl ester transfer protein, 
which blocks LDL catabolism and secretion in 
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hepatocytes (23). This will result in reduced plasma 
LDL. As mentioned above, all these changes are 
temporary, and the negative feedback will balance these 
changes over time. However, the changes in LDL are 
greater than HDL; which results in lower LDL/HDL 
ratio as one of the most important risk factors for CVDs 
(11), but infliximab will stop this chain. Although, our 
study demonstrated an insignificant 5% increase in LDL 
and TG, HDL increases by nearly 20%, approving the 
above theories.  
 
TNF and weight 
Our study demonstrated that infliximab therapy 
would result in significant 1-3 kg weight gain in 
psoriatic patients within a 24 weeks period; furthermore, 
a significant correlation was found between BMI and 
leptin. Although there are not so many studies regarding 
this issue, Gisondi et al., (20) and Briot et al., (21) 
demonstrated the same results. Basic studies have 
suggested that these weight gains are not “fat” gain and 
anti-TNF agents increase lean body mass. We should 
know that not all patients exhibit this weight gain, which 
can be due to immunologic reaction differences or 
genomic pool. The reason is still unknown. Molecular 
studies have demonstrated that TNF along with 
cachectin can result in the catabolism of myocytes and 
therefore, the anti-TNF agent can block this pathway. 
Furthermore, studies showed that infliximab increased 
appetite (20-21). The most important difference between 
our result and other published literature was the negative 
significant correlation between PASI score and BMI; not 
found in other studies. Furthermore, these BMI increase 
is frequently seen in “fatter” patients. Thus, it is 
recommended that patients with higher BMI exert more 
diet control while receiving Infliximab because psoriasis 
itself (rather than other etiologies such as depression, 
immobility, and corticosteroid treatment) can increase 
their weight by 10-15%; also demonstrated in other 
diseases such as Crohn’s disease. Nakahigashi et al., 
(22) have suggested that infliximab treatment can induce 
food craving (due to better health quality), leptin 
increase (seen in our study) and infliximab itself. 
However, we cannot leave the role of Insulin 
resistance unnoticed. A review study has demonstrated 
that infliximab reduced insulin resistance. But there are 
not too many evidence to enroll it as an important factor 
of weight in psoriasis; while most of the patients in our 
study were young. 
While our study did demonstrate interesting results, 
we should be aware of our study’s limitations: 1-low 
sample size due to strict exclusion criteria; and 2-lack of 
the control group. We suggest studies with higher 
sample sizes and more molecular concerns. 
We studied leptin, lipid profile and BMI changes in 
psoriatic patients treated with infliximab. Results 
demonstrated a dramatic decrease in PASI, changes in 
BMI and HDL and increased in leptin; somewhat 
correlated to each other. These results suggest that 
patients taking infliximab should take more care of their 
weight and lipid profile, while on treatment. 
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